News
Sementis CEO Dr Anne Collins is recipient of DMTC’s Collaboration Award
February 2024 Sementis was delighted to be recognised at the 2024 DMTC Annual Conference, and our CEO Dr Anne Collins...
November 2018
Australian biotechnology firm Sementis has entered into a research and development (R&D) partnership with UK-based Enesi Pharma for the development of potential vaccine candidates to treat peanut allergy and chikungunya/Zika infection.
Read more in Pharmaceutical Technology here.
News
February 2024 Sementis was delighted to be recognised at the 2024 DMTC Annual Conference, and our CEO Dr Anne Collins...
News
September 2023 Biotechnology company Sementis will advance its position at the forefront of vaccine technology with the...
News
January 2023 Sementis has exciting news. We’re pleased to announce that we’ve been awarded a $3 million Federal...